APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Disease Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Respiratory Disease Vaccine Market Outlook and Growth Opportunities 2026

29 December 2025197 pages

Choose your research edition.

Industry ResearchRespiratory Disease Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Disease Vaccine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Respiratory Disease Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Disease Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Disease Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Respiratory Disease Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Respiratory Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Respiratory Disease Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Respiratory Disease Vaccine market include Sanofi SA, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., SINOVAC, Serum Institute of India Pvt. Ltd., Novavax, GSK plc. and Emergent BioSolutions Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Disease Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Disease Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Disease Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Disease Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Disease Vaccine Segment by Company

Sanofi SA

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Pfizer Inc.

SINOVAC

Serum Institute of India Pvt. Ltd.

Novavax

GSK plc.

Emergent BioSolutions Inc.

AstraZeneca

Respiratory Disease Vaccine Segment by Type

Live Attenuated

Inactivated

Others

Respiratory Disease Vaccine Segment by Application

Flu

Pneumonia

Others

Respiratory Disease Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Respiratory Disease Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Respiratory Disease Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Respiratory Disease Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Respiratory Disease Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Disease Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Disease Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Disease Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Disease Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Respiratory Disease Vaccine industry.

Chapter 3: Detailed analysis of Respiratory Disease Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Respiratory Disease Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Respiratory Disease Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Respiratory Disease Vaccine Industry Trends Table 2. Respiratory Disease Vaccine Industry Drivers Table 3. Respiratory Disease Vaccine Industry Opportunities and Challenges Table 4. Respiratory Disease Vaccine Industry Restraints Table 5. Global Respiratory Disease Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Respiratory Disease Vaccine Revenue Share by Company (2021-2026) Table 7. Global Respiratory Disease Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Respiratory Disease Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Respiratory Disease Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Respiratory Disease Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Respiratory Disease Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Respiratory Disease Vaccine Company, Product Type & Application Table 13. Global Respiratory Disease Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Disease Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Live Attenuated Table 18. Significant Companies of Inactivated Table 19. Significant Companies of Others Table 20. Global Respiratory Disease Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Respiratory Disease Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Respiratory Disease Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Respiratory Disease Vaccine Sales Volume Share by Type (2021-2026) Table 24. Global Respiratory Disease Vaccine Sales Volume Share by Type (2027-2032) Table 25. Global Respiratory Disease Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Respiratory Disease Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Respiratory Disease Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Respiratory Disease Vaccine Sales Value Share by Type (2021-2026) Table 29. Global Respiratory Disease Vaccine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Flu Table 31. Significant Companies of Pneumonia Table 32. Significant Companies of Others Table 33. Global Respiratory Disease Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Respiratory Disease Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Respiratory Disease Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Respiratory Disease Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Respiratory Disease Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Respiratory Disease Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Respiratory Disease Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Respiratory Disease Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Respiratory Disease Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Respiratory Disease Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Respiratory Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Respiratory Disease Vaccine Sales by Region (2021-2026) & (K Units) Table 45. Global Respiratory Disease Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Respiratory Disease Vaccine Sales by Region (2027-2032) & (K Units) Table 47. Global Respiratory Disease Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Respiratory Disease Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Respiratory Disease Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Respiratory Disease Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Respiratory Disease Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Respiratory Disease Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Respiratory Disease Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Respiratory Disease Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Respiratory Disease Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Respiratory Disease Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 58. Global Respiratory Disease Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 60. Global Respiratory Disease Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Respiratory Disease Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Respiratory Disease Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Respiratory Disease Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Respiratory Disease Vaccine Sales Value Market Share by Country (2027-2032) Table 65. Sanofi SA Company Information Table 66. Sanofi SA Business Overview Table 67. Sanofi SA Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Sanofi SA Respiratory Disease Vaccine Product Portfolio Table 69. Sanofi SA Recent Development Table 70. Johnson & Johnson Services, Inc. Company Information Table 71. Johnson & Johnson Services, Inc. Business Overview Table 72. Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Product Portfolio Table 74. Johnson & Johnson Services, Inc. Recent Development Table 75. Merck & Co., Inc. Company Information Table 76. Merck & Co., Inc. Business Overview Table 77. Merck & Co., Inc. Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck & Co., Inc. Respiratory Disease Vaccine Product Portfolio Table 79. Merck & Co., Inc. Recent Development Table 80. Pfizer Inc. Company Information Table 81. Pfizer Inc. Business Overview Table 82. Pfizer Inc. Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Pfizer Inc. Respiratory Disease Vaccine Product Portfolio Table 84. Pfizer Inc. Recent Development Table 85. SINOVAC Company Information Table 86. SINOVAC Business Overview Table 87. SINOVAC Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. SINOVAC Respiratory Disease Vaccine Product Portfolio Table 89. SINOVAC Recent Development Table 90. Serum Institute of India Pvt. Ltd. Company Information Table 91. Serum Institute of India Pvt. Ltd. Business Overview Table 92. Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Product Portfolio Table 94. Serum Institute of India Pvt. Ltd. Recent Development Table 95. Novavax Company Information Table 96. Novavax Business Overview Table 97. Novavax Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Novavax Respiratory Disease Vaccine Product Portfolio Table 99. Novavax Recent Development Table 100. GSK plc. Company Information Table 101. GSK plc. Business Overview Table 102. GSK plc. Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. GSK plc. Respiratory Disease Vaccine Product Portfolio Table 104. GSK plc. Recent Development Table 105. Emergent BioSolutions Inc. Company Information Table 106. Emergent BioSolutions Inc. Business Overview Table 107. Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Emergent BioSolutions Inc. Respiratory Disease Vaccine Product Portfolio Table 109. Emergent BioSolutions Inc. Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Respiratory Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. AstraZeneca Respiratory Disease Vaccine Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Respiratory Disease Vaccine Distributors List Table 118. Respiratory Disease Vaccine Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Respiratory Disease Vaccine Product Image Figure 2. Global Respiratory Disease Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Respiratory Disease Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Respiratory Disease Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Respiratory Disease Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Live Attenuated Image Figure 10. Inactivated Image Figure 11. Others Image Figure 12. Global Respiratory Disease Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Respiratory Disease Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Respiratory Disease Vaccine Sales Volume Share by Type (2021-2032) Figure 15. Global Respiratory Disease Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Respiratory Disease Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Respiratory Disease Vaccine Sales Value Share by Type (2021-2032) Figure 18. Flu Image Figure 19. Pneumonia Image Figure 20. Others Image Figure 21. Global Respiratory Disease Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Respiratory Disease Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Respiratory Disease Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Respiratory Disease Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Respiratory Disease Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Respiratory Disease Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Respiratory Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Respiratory Disease Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Respiratory Disease Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Respiratory Disease Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Respiratory Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Respiratory Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Respiratory Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Respiratory Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Respiratory Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Respiratory Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Respiratory Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Respiratory Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Respiratory Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Respiratory Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Respiratory Disease Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Respiratory Disease Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Live Attenuated
  • Inactivated
  • Others
Applications
  • Flu
  • Pneumonia
  • Others
Companies covered
  • Sanofi SA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • SINOVAC
  • Serum Institute of India Pvt. Ltd.
  • Novavax
  • GSK plc.
  • Emergent BioSolutions Inc.
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Respiratory Disease Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Respiratory Disease Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Respiratory Disease Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Respiratory Disease Vaccine Market Dynamics
  1. 2.1 Respiratory Disease Vaccine Industry Trends
  2. 2.2 Respiratory Disease Vaccine Industry Drivers
  3. 2.3 Respiratory Disease Vaccine Industry Opportunities and Challenges
  4. 2.4 Respiratory Disease Vaccine Industry Restraints
3 Respiratory Disease Vaccine Market by Company
  1. 3.1 Global Respiratory Disease Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Respiratory Disease Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Respiratory Disease Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Respiratory Disease Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Respiratory Disease Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Respiratory Disease Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Respiratory Disease Vaccine Company Product Type and Application
  8. 3.8 Global Respiratory Disease Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Respiratory Disease Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Respiratory Disease Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Respiratory Disease Vaccine Market by Type
  1. 4.1 Respiratory Disease Vaccine Type Introduction
  2. 4.1.1 Live Attenuated
  3. 4.1.2 Inactivated
  4. 4.1.3 Others
  5. 4.2 Global Respiratory Disease Vaccine Sales Volume by Type
  6. 4.2.1 Global Respiratory Disease Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Respiratory Disease Vaccine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Respiratory Disease Vaccine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Respiratory Disease Vaccine Sales Value by Type
  10. 4.3.1 Global Respiratory Disease Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Respiratory Disease Vaccine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Respiratory Disease Vaccine Sales Value Share by Type (2021-2032)
5 Respiratory Disease Vaccine Market by Application
  1. 5.1 Respiratory Disease Vaccine Application Introduction
  2. 5.1.1 Flu
  3. 5.1.2 Pneumonia
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Disease Vaccine Sales Volume by Application
  6. 5.2.1 Global Respiratory Disease Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Disease Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Respiratory Disease Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Respiratory Disease Vaccine Sales Value by Application
  10. 5.3.1 Global Respiratory Disease Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Respiratory Disease Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Respiratory Disease Vaccine Sales Value Share by Application (2021-2032)
6 Respiratory Disease Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Respiratory Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Disease Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Disease Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Respiratory Disease Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Respiratory Disease Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Respiratory Disease Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Respiratory Disease Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Respiratory Disease Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Respiratory Disease Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Respiratory Disease Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Respiratory Disease Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Respiratory Disease Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Respiratory Disease Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Respiratory Disease Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Respiratory Disease Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Respiratory Disease Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Respiratory Disease Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Respiratory Disease Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Respiratory Disease Vaccine Sales Value Share by Country, 2025 VS 2032
7 Respiratory Disease Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Respiratory Disease Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Respiratory Disease Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Respiratory Disease Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Respiratory Disease Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Respiratory Disease Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Respiratory Disease Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Respiratory Disease Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Respiratory Disease Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Respiratory Disease Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Respiratory Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Respiratory Disease Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi SA
  2. 8.1.1 Sanofi SA Company Information
  3. 8.1.2 Sanofi SA Business Overview
  4. 8.1.3 Sanofi SA Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi SA Respiratory Disease Vaccine Product Portfolio
  6. 8.1.5 Sanofi SA Recent Developments
  7. 8.2 Johnson & Johnson Services, Inc.
  8. 8.2.1 Johnson & Johnson Services, Inc. Company Information
  9. 8.2.2 Johnson & Johnson Services, Inc. Business Overview
  10. 8.2.3 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Product Portfolio
  12. 8.2.5 Johnson & Johnson Services, Inc. Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. Respiratory Disease Vaccine Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. Respiratory Disease Vaccine Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 SINOVAC
  26. 8.5.1 SINOVAC Company Information
  27. 8.5.2 SINOVAC Business Overview
  28. 8.5.3 SINOVAC Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 SINOVAC Respiratory Disease Vaccine Product Portfolio
  30. 8.5.5 SINOVAC Recent Developments
  31. 8.6 Serum Institute of India Pvt. Ltd.
  32. 8.6.1 Serum Institute of India Pvt. Ltd. Company Information
  33. 8.6.2 Serum Institute of India Pvt. Ltd. Business Overview
  34. 8.6.3 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Product Portfolio
  36. 8.6.5 Serum Institute of India Pvt. Ltd. Recent Developments
  37. 8.7 Novavax
  38. 8.7.1 Novavax Company Information
  39. 8.7.2 Novavax Business Overview
  40. 8.7.3 Novavax Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novavax Respiratory Disease Vaccine Product Portfolio
  42. 8.7.5 Novavax Recent Developments
  43. 8.8 GSK plc.
  44. 8.8.1 GSK plc. Company Information
  45. 8.8.2 GSK plc. Business Overview
  46. 8.8.3 GSK plc. Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GSK plc. Respiratory Disease Vaccine Product Portfolio
  48. 8.8.5 GSK plc. Recent Developments
  49. 8.9 Emergent BioSolutions Inc.
  50. 8.9.1 Emergent BioSolutions Inc. Company Information
  51. 8.9.2 Emergent BioSolutions Inc. Business Overview
  52. 8.9.3 Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Emergent BioSolutions Inc. Respiratory Disease Vaccine Product Portfolio
  54. 8.9.5 Emergent BioSolutions Inc. Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Respiratory Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Respiratory Disease Vaccine Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Disease Vaccine Value Chain Analysis
  2. 9.1.1 Respiratory Disease Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Disease Vaccine Sales Mode & Process
  6. 9.2 Respiratory Disease Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Disease Vaccine Distributors
  9. 9.2.3 Respiratory Disease Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst